Skip to main content
Skip to main content

AAP Gateway

Advanced Search »
  • Login
  • AAP Policy
  • Topic/Program Collections
  • Journal Info
  • Alerts
  • Contact Us
  • aap.org

Menu

  • AAP Grand Rounds
  • AAP News
  • Hospital Pediatrics
  • NeoReviews
  • Pediatrics
  • Pediatrics in Review
  • Journal CME Quizzes
  • Pediatric Collections
  • AAP Career Center
  • Current AAP Policy
  • AAP Journals Catalog

AAP News

  • Health Alerts: Infant ibuprofen, jogging strollers, and more
  • Liquid herbal supplement for infants recalled
  • First pediatrician elected to Congress prioritizes health care, gun safety
  • Merck HepB vaccine shortage extended through 2019
  • CDC flu report: 34 children have died

  • Login
  • AAP Policy
  • Topic/Program Collections
  • Journal Info
  • Alerts
  • Contact Us
  • aap.org

Advertising Disclaimer »

Tools and Links

Journals Blog
February 13, 2018

Treatment Studies of Nephrotic Syndrome Also Offer Insight into Pathogenesis

Bud Wiederman, MD, MA, Evidence eMended Editor, Grand Rounds

This is a retrospective observational study of a randomized controlled trial. Sound confusing? It's really not, and although it's a small study it does offer some fresh insight into pathogenesis and treatment of complicated nephrotic syndrome.

Source: Kamei K, Ishikura K, Sako M, et al. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol. 2017;32(11):2071-2078; doi:10.1007/s00467-017-3718-0. See AAP Grand Rounds commentary by Dr. Pamela Singer (subscription required).

It's not hard to imagine how a randomized controlled trial (RCT) morphed into an observational study. In this report on rituximab use for complicated (frequently relapsing or steroid-dependent) nephrotic syndrome, the initial study was a randomized, placebo-controlled trial of rituximab in 52 (mostly) children with these conditions. Results of a preplanned interim analysis showed superiority of rituximab over placebo in lowering relapses over a 12 month period. After this RCT was completed, patients originally receiving placebo were offered entry into a second study on the pharmacokinetics of rituximab, which allowed for observation of 2 cohorts going forward (or backward, if you will!): group A did not need additional rituximab or immunosuppressive agents during the observation period, and group B did require such treatments. This is a somewhat complicated analysis because the use of treatments after the RCT ended was determined by the individual treating physicians.

When the statistical smoke cleared, the authors point out a number of interesting conclusions. First, although rituximab does appear to have benefit in these complicated nephrotic syndrome circumstances, most patients receiving this agent will still experience more relapses down the road. However, the subgroup of patients who were doing well enough to enable discontinuation of steroids and immunosuppressives at the time of rituximab use seemed to be more likely to achieve long-term remission of their disease, compared to patients who needed to remain on steroids and/or immunosuppressives. This could mean that immunosuppressives in this "mild" group could be withheld after rituximab treatment.

Also, based on observations of B-cell depletion and recovery after rituximab, the authors speculate that the role of B cells in the pathogenesis of nephrotic syndrome might be indirect, involving some mechanism of the interaction between T and B cells. This could point the way to future treatment development and clinical trials.

One final note on the reporting of the article itself. Figure 3 in the study is an excellent example of graphical display of a lot of information in a form that conveys a great deal of understanding of the data. Sadly, I can't link directly to it due to copyright protections, but readers who have access to that journal should take a look. For all of you, please look at Charles Joseph Minard's map of Napoleon's 1812 Russia campaign, thought to be one of the best graphical displays of complex information in history. (I have a framed print hanging in my office, staring at me every day!) After all, Evidence-Based Medicine is nothing if we can't explain it to our patients in terms that they can use to make healthcare choices.

  • Steroid Minimization Regimens for Management of Nephrotic Syndrome
  • Facebook
Copyright © 2018 American Academy of Pediatrics

 

Advertising Disclaimer »

Email

Thank you for your interest in spreading the word on AAP Gateway.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treatment Studies of Nephrotic Syndrome Also Offer Insight into Pathogenesis
(Your Name) has sent you a message from AAP Gateway
(Your Name) thought you would like to see the AAP Gateway web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
11 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Share
Treatment Studies of Nephrotic Syndrome Also Offer Insight into Pathogenesis
Bud Wiederman
AAP News Dec 1969,
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
PDF
  • Digital Edition Current Issue
  • Latest Daily News
  • Archives
  • Collections
  • Columns
  • Advertising
  • Subscribe to AAP News Magazine
Back to top

     

Copyright © 2019 by American Academy of Pediatrics

International Access »

Terms of Use
The American Academy of Pediatrics (AAP) takes the issue of privacy very seriously. See our Privacy Statement for information about how AAP collects, uses, safeguards and discloses the information collected on our Website from visitors and by means of technology.
FAQ

AAP Pediatrics